Fax (215) 596-7614
Cost effectiveness of gene expression profiling for early stage breast cancer
A decision-analytic model
Article first published online: 22 FEB 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 20, pages 5163–5170, 15 October 2012
How to Cite
Yang, M., Rajan, S. and Issa, A. M. (2012), Cost effectiveness of gene expression profiling for early stage breast cancer. Cancer, 118: 5163–5170. doi: 10.1002/cncr.27443
- Issue published online: 5 OCT 2012
- Article first published online: 22 FEB 2012
- Manuscript Accepted: 6 DEC 2011
- Manuscript Revised: 23 NOV 2011
- Manuscript Received: 18 SEP 2011
- gene-expression profiling;
- breast cancer;
- Markov modeling;
- health economics
Gene expression profiling (GEP) is being used increasingly for risk stratification to identify women with lymph node-negative, estrogen receptor-positive, early stage breast cancer who are most likely to benefit from adjuvant chemotherapy. The authors of this report evaluated the cost effectiveness of recurrence score-guided treatment using 2 commercially available GEP tests, Oncotype DX (Genomic Health, Redwood City, Calif) and MammaPrint (Agendia Inc., Irvine, Calif), from a third-party payer's perspective.
A 10-year Markov model was developed to compare the costs and quality-adjusted life-years (QALYs) of treatment decisions guided by either Oncotype DX or MammaPrint in a hypothetical cohort of women with early stage, lymph node-negative, estrogen receptor-positive breast cancer who may experience recurrence. Outcomes included no recurrence, recurrence, and death. The costs considered included gene test costs, the costs of adjuvant chemotherapy and other chemotherapy (including premedication, oncology visits, and monitoring for adverse events), the cost of treating recurrence, costs associated with the treatment of adverse events, and end-of-life care costs.
The model demonstrated that the patients who received the Oncotype DX test to guide treatment spent $27,882 (in US dollars) and gained 7.364 QALYs, whereas patients who received the MammaPrint test to guide treatment spent $21,598 and gained 7.461 QALYs. Sensitivity analyses demonstrated that the results were robust to changes in all parameters.
The model suggested that MammaPrint is a more cost-effective GEP test compared with Oncotype DX at a threshold willingness-to-pay of $50,000 per QALY. Because Oncotype DX is the most frequently used GEP in clinical practice in the United States, the authors concluded that the current findings have implications for health policy, particularly health insurance reimbursement decisions. Cancer 2012. © 2012 American Cancer Society.